Relevance of Positron-Emission Therapy for Optimization of Treatment of Advanced Hodgkin’s Lymphoma Using Intensive ЕАСОРР-14 Program

Author:

Demina Elena Andreevna1,Leont'eva A.A.1,Tumyan G.S.1,Ryabukhina Yu.E1,Medvedovskaya E.G.1,Trofimova O.P.1,Sotnikov V.M.2,Larionova V.B.1,Paramonova E.V.1,Manzyuk L.V.1,Kokosadze N.V.1,Mukhortova O.V.3,Aslanidi I.P.3,Zaitseva A.Yu.4,Radkevich L.A.4,Rudas M.S.5,Manukova V.A.5,Osmanov E.A.1

Affiliation:

1. NN Blokhin Russian Cancer Research Center

2. Russian Scientific Center of Roentgenoradiology under the Ministry of Health of the Russian Federation

3. AN Bakulev Scientific Center for Cardiovascular Surgery

4. Clinical Hospital No. 1 under the Administration of Presidential Affairs of the Russian Federation

5. Central Clinical Hospital under the Administration of Presidential Affairs of the Russian Federation

Abstract

Aim. To evaluate the relevance of the positron-emission therapy (PET) for optimization of the therapy of advanced Hodgkin's lymphoma (HL) using the intensive EACOPP-14 program. Materials & Methods. 91 patients with advanced HL (IIX-IIE, III-IV) received the treatment according to the “ЛХМосква1-3” protocol over the period from November 2009 to February 2015, and then the treatment was analyzed. The median age was 29 years (range: 17-50); there were 42 men (46.3 %) and 49 (53.7 %) women. The treatment included 6 cycles of polychemotherapy according to the regimen ЕА(50)С0РР-14 ± radiation therapy. The radiation therapy was performed in 66 patients (72.5 %) after the completion of the chemotherapy. The cumulative focal dose was 30 Gy onto the areas of residual lesions and/or initially large tumor masses. Results. PET performed during the initial HL diagnosing permited to identify new areas of neoplastic lesions without changes in staging and treatment scheme, as well as specify areas and field size of planned radiation consolidation. The paper confirms the prognostic value of the intermediate PET in patients with advanced HL during the intensive first-line chemotherapy. The intensive therapy at the beginning of the treatment program is associated with higher chances for survival for patients with extremely unfavorable prognosis. After completion of the drug therapy, negative PET findings had a higher prognostic value, than the positive ones. The analysis of the relevance of residual tumor dimensions in the PET negative group demonstrated that the relapses were more common, if the residual tumor was more than 4.5 cm (according to CT findings). Conclusion. This study confirmed that it reasonable to discuss the discontinuation of the radiation therapy in patients with advanced HL, negative PET findings and small (< 2.5 cm) residual tumor after the intensive ЕАСОРР-14 program. This tactics permits avoiding a number of delayed complications.

Publisher

Practical Medicine Publishing House

Subject

Oncology,Hematology

Reference33 articles.

1. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386-95. doi: 10.1056/nejmoa022473.

2. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-54. doi: 10.1200/ jco.2008.19.8820.

3. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943-52. doi: 10.1016/ s1470-2045(13)70341-3.

4. Hoppe RT. Hodgkin’s disease: Second cancer after treatment Hodgkin’s disease: Complications of therapy and excess mortality. Ann Oncol. 1997;8(1):S115-8. doi: 10.1093/annonc/8.suppl_1.s115.

5. Шахтарина С.В., Даниленко А.А., Павлов В.В. Злокачественные новообразования у больных лимфомой Ходжкина после лучевой терапии по радикальной программе и комбинированной химиолучевой терапии. Клиническая онкогемотология. 2008;3(1):246-51. [Shakhtarina SV, Danilenko AA, Pavlov VV. Secondary malignancies in Hodgkin's disease patients after radiotherapy and combined chemo-radiotherapy. Klinicheskaya onkogematologiya. 2008;3(1):246-51. (In Russ)]

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3